What is the role of steroids in pneumonia therapy?

Current Opinion in Infectious Diseases

Volumn 25, Issue 2, 2012, Pages 199-204

  Póvoa, Pedro ^a,b   Salluh, Jorge I F ^c,d  

^a HOSPITAL DE SÃO FRANCISCO XAVIER   (Portugal)

^b UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^c D OR INSTITUTE FOR RESEARCH AND EDUCATION IDOR   (Brazil)

^d INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

community acquired pneumonia; H1N1 infection; hospital acquired pneumonia; steroids

Indexed keywords

CEFTRIAXONE; DEXAMETHASONE; HYDROCORTISONE; LEVOFLOXACIN; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; STEROID;

ANTIBIOTIC THERAPY; ARTIFICIAL VENTILATION; COMMUNITY ACQUIRED PNEUMONIA; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL ADMISSION; HUMAN; HYPERGLYCEMIA; INFECTION RISK; INFLUENZA A (H1N1); LENGTH OF STAY; PATHOGENESIS; PNEUMONIA; REVIEW; STEROID THERAPY; SUPERINFECTION; TREATMENT OUTCOME;

CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; PNEUMONIA; STEROIDS;

EID: 84858006819     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32834f44c7     Document Type: Review

References (43)

1. Marik PE, Pastores SM, Annane D, et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 2008; 36:1937-1949.
2. Rano A, Agusti C, Sibila O, et al. Associated inflammatory response in pneumonia: role of adjunctive therapy with glucocorticoids. Curr Opin Infect Dis 2006; 19:179-184. (Pubitemid 44139148)
3. Salluh JI, Povoa P, Soares M, et al. The role of corticosteroids in severe community-acquired pneumonia: a systematic review. Crit Care 2008; 12: R76.
4. Chen Y, Li K, Pu H, et al. Corticosteroids for pneumonia. Cochrane Database Syst Rev 2011; CD007720.
5. Salluh JI, Bozza FA, Japiassu AM, et al. Corticosteroids in sepsis: pathophysiological rationale and the selection of patients. Endocr Metab Immune Disord Drug Targets 2010; 10:266-273.
6. Lekkou A, Karakantza M, Mouzaki A, et al. Cytokine production and monocyte HLA-DR expression as predictors of outcome for patients with community-acquired severe infections. Clin Diagn Lab Immunol 2004; 11:161-167. (Pubitemid 38090671)
7. Fernandez-Serrano S, Dorca J, Coromines M, et al. Molecular inflammatory responses measured in blood of patients with severe community-acquired pneumonia. Clin Diagn Lab Immunol 2003; 10:813-820. (Pubitemid 37129493)
8. Kellum JA, Kong L, Fink MP, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med 2007; 167:1655-1663. (Pubitemid 47280347)
9. Bermejo-Martin JF, Ortiz de Lejarazu R, Pumarola T, et al. Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza. Crit Care 2009; 13:R201.
10. Prigent H, Maxime V, Annane D. Clinical review: corticotherapy in sepsis. Crit Care 2004; 8:122-129. (Pubitemid 38436420)
11. Jaeschke R, Angus DC. Living with uncertainty in the intensive care unit: should patients with sepsis be treated with steroids? JAMA 2009; 301: 2388-2390.
12. Marik P, Kraus P, Sribante J, et al. Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. A randomized controlled study. Chest 1993; 104:389-392. (Pubitemid 23229504)
13. Mikami K, Suzuki M, Kitagawa H, et al. Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung 2007; 185:249-255. (Pubitemid 47397487)
14. Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005; 171:242-248.
15. Garcia-Vidal C, Calbo E, Pascual V, et al. Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur Respir J 2007; 30:951-956. (Pubitemid 351194800)
16. Snijders D, Daniels JM, de Graaff CS, et al. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med 2010; 181:975-982. The first large randomized controlled trial showing no impact of adjunctive therapy with steroids on mortality in mild-to-moderate community-acquired pneumonia. Steroids were associated with a significant increase in late failures.
17. Fernandez-Serrano S, Dorca J, Garcia-Vidal C, et al. Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial. Crit Care 2011; 15:R96.
18. Meijvis SC, Hardeman H, Remmelts HH, et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377:2023-2030. A recent, large, randomized controlled trial showing no impact of adjunctive therapy with steroids on mortality in mild-to-moderate community-acquired pneumonia. Steroids were associated with higher rate of adverse effects, namely hyperglycemia and superinfections.
19. Salluh JI, Soares M, Povoa P. Corticosteroids in severe community-acquired pneumonia: the path we choose depends on where we want to get. Crit Care 2011; 15:137.
20. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 (Suppl. 2):S27-S72. (Pubitemid 46290553)
21. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64 (Suppl. 3):iii1-iii55.
22. Salluh JI, Soares M, Coelho LM, et al. Impact of systemic corticosteroids on the clinical course and outcomes of patients with severe community-acquired pneumonia: a cohort study. J Crit Care 2011; 26:193-200. This large observational study showed no impact on mortality of steroids in severe community-acquired pneumonia. In addition, steroids were associated with longer ICU and hospital stay and with higher rate of superinfections.
23. Chon GR, Lim CM, Koh Y, et al. Analysis of systemic corticosteroid usage and survival in patients requiring mechanical ventilation for severe communityacquired pneumonia. J Infect Chemother 2010; 17:449-455.
24. Papazian L, Forel JM, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med 2010; 363:1107-1116, and supplementary appendix. In this large randomized controlled trial on neuromuscular blockers in ARDS, the adjunctive therapy with steroids significantly increased the mortality both in the intervention and in the placebo arm.
25. Noel V, Lortholary O, Casassus P, et al. Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus. Ann Rheum Dis 2001; 60:1141-1144. (Pubitemid 33096079)
26. Agusti C, Rano A, Filella X, et al. Pulmonary infiltrates in patients receiving long-term glucocorticoid treatment: etiology, prognostic factors, and associated inflammatory response. Chest 2003; 123:488-498. (Pubitemid 36269435)
27. Yende S, D'Angelo G, Kellum JA, et al. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med 2008; 177:1242-1247. (Pubitemid 351860933)
28. Marik PE. Critical illness-related corticosteroid insufficiency. Chest 2009; 135:181-193.
29. Garcia-Vidal C, Carratala J, Fernandez-Sabe N, et al. Aetiology of, and risk factors for, recurrent community-acquired pneumonia. Clin Microbiol Infect 2009; 15:1033-1038.
30. Roquilly A, Mahe PJ, Seguin P, et al. Hydrocortisone therapy for patients with multiple trauma: the randomized controlled HYPOLYTE study. JAMA 2011; 305:1201-1209.
31. Salluh JI, Povoa P. Hydrocortisone and treatment of multiple trauma. JAMA 2011; 306:41; author reply 42.
32. Annane D. Pro: the illegitimate crusade against corticosteroids for severe H1N1 pneumonia. Am J Respir Crit Care Med 2011; 183:1125-1126.
33. Matthay MA, Liu KD. Con: corticosteroids are not indicated for treatment of acute lung injury from H1N1 viral pneumonia. Am J Respir Crit Care Med 2011; 183:1127-1128.
34. Bermejo-Martin JF, Martin-Loeches I, Rello J, et al. Host adaptive immunity deficiency in severe pandemic influenza. Crit Care 2010; 14:R167.
35. Lat A, Bhadelia N, Miko B, et al. Invasive aspergillosis after pandemic (H1N1) 2009. Emerg Infect Dis 2010; 16:971-973.
36. Souza TM, Salluh JI, Bozza FA, et al. H1N1pdm influenza infection in hospitalized cancer patients: clinical evolution and viral analysis. PLoS One 2010; 5:e14158.
37. Quispe-Laime AM, Bracco JD, Barberio PA, et al. H1N1 influenza A virus-associated acute lung injury: response to combination oseltamivir and prolonged corticosteroid treatment. Intensive Care Med 2010; 36:33-41.
38. Xi X, Xu Y, Jiang L, et al. Hospitalized adult patients with 2009 influenza A(H1N1) in Beijing, China: risk factors for hospital mortality. BMC Infect Dis 2010; 10:256.
39. Martin-Loeches I, Lisboa T, Rhodes A, et al. Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection. Intensive Care Med 2011; 37:272-283. The first large report pointing to the potential harmful effect of adjunctive therapy with steroids in severe H1N1v pneumonia.
40. Brun-Buisson C, Richard JC, Mercat A, et al. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med 2011; 183:1200-1206. A large prospective observational study demonstrating a deleterious effect of adjunctive therapy with steroids on mortality in severe H1N1v pneumonia.
41. Kim SH, Hong SB, Yun SC, et al. Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores. Am J Respir Crit Care Med 2011; 183:1207-1214. A large prospective observational study demonstrating a deleterious effect on mortality of the adjunctive therapy with steroids in severe H1N1v pneumonia as well as a significant increase in the rate of superinfections.
42. Van de Beek D, de Gans J, McIntyre P, et al. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 2007; CD004405.
43. Briel M, Bucher HC, Boscacci R, et al. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV-infection. Cochrane Database Syst Rev 2006; 3:CD006150